TY - JOUR
T1 - Prognostic significance of defining L-cell type on the biologic behavior of rectal neuroendocrine tumors in relation with pathological parameters
AU - Sohn, Jin Hee
AU - Cho, Mee Yon
AU - Park, Yangsoon
AU - Kim, Hyunki
AU - Kim, Woo Ho
AU - Kim, Joon Mee
AU - Jung, Eun Sun
AU - Kim, Kyoung Mee
AU - Lee, Jae Hyuk
AU - Chang, Hee Kyung
AU - Park, Do Youn
AU - Joo, Mee
AU - Kim, Sujin
AU - Moon, Woo Sung
AU - Kang, Mi Seon
AU - Jin, So Young
AU - Kang, Yun Kyung
AU - Yoon, Sun Och
AU - Han, Hye Seung
AU - Choi, Eun Hee
N1 - Publisher Copyright:
© 2015 by the Korean Cancer Association.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2015
Y1 - 2015
N2 - Purpose In 2010, the World Health Organization categorized L-cell type neuroendocrine tumors (NETs) as tumors of uncertain malignancy, while all others were classified as malignant. However, the diagnostic necessity of L-cell immunophenotyping is unclear, as are tumor stage and grade that may guide diagnosis and management. To clarify the predictive markers of rectal neuroendocrine neoplasms (NENs), 5- and 10-year overall survival (OS) was analyzed by pathological parameters including L-cell phenotype. Materials and Methods A total of 2,385 rectal NENs were analyzed from our previous multicenter study and a subset of 170 rectal NENs was immunophenotyped. Results In univariate survival analysis, tumor grade (p < 0.0001), extent (p < 0.0001), size (p < 0.0001), lymph node metastasis (p = 0.0063), and L-cell phenotype (p < 0.0001) showed significant correlation with the prognosis of rectal NENs; however, none of these markers achieved independent significance in multivariate analysis. The 10-year OS of tumors of NET grade 1, < 10 mm, the mucosa/submucosa was 97.58%, 99.47%, and 99.03%, respectively. L-Cell marker, glucagon II (GLP-1 & 2), with a cut off score of > 10, is useful in defining L-Cell type. In this study, an L-cell immunophenotype was found in 83.5% of all rectal NENs and most, but not all L-cell type tumors were NET G1, small (< 10 mm) and confined to the mucosa/submucosa. Conclusion From these results, the biological behavior of rectal NENs does not appear to be determined by L-cell type alone but instead by a combination of pathological parameters.
AB - Purpose In 2010, the World Health Organization categorized L-cell type neuroendocrine tumors (NETs) as tumors of uncertain malignancy, while all others were classified as malignant. However, the diagnostic necessity of L-cell immunophenotyping is unclear, as are tumor stage and grade that may guide diagnosis and management. To clarify the predictive markers of rectal neuroendocrine neoplasms (NENs), 5- and 10-year overall survival (OS) was analyzed by pathological parameters including L-cell phenotype. Materials and Methods A total of 2,385 rectal NENs were analyzed from our previous multicenter study and a subset of 170 rectal NENs was immunophenotyped. Results In univariate survival analysis, tumor grade (p < 0.0001), extent (p < 0.0001), size (p < 0.0001), lymph node metastasis (p = 0.0063), and L-cell phenotype (p < 0.0001) showed significant correlation with the prognosis of rectal NENs; however, none of these markers achieved independent significance in multivariate analysis. The 10-year OS of tumors of NET grade 1, < 10 mm, the mucosa/submucosa was 97.58%, 99.47%, and 99.03%, respectively. L-Cell marker, glucagon II (GLP-1 & 2), with a cut off score of > 10, is useful in defining L-Cell type. In this study, an L-cell immunophenotype was found in 83.5% of all rectal NENs and most, but not all L-cell type tumors were NET G1, small (< 10 mm) and confined to the mucosa/submucosa. Conclusion From these results, the biological behavior of rectal NENs does not appear to be determined by L-cell type alone but instead by a combination of pathological parameters.
UR - http://www.scopus.com/inward/record.url?scp=84946724912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946724912&partnerID=8YFLogxK
U2 - 10.4143/crt.2014.238
DO - 10.4143/crt.2014.238
M3 - Article
C2 - 25715764
AN - SCOPUS:84946724912
VL - 47
SP - 813
EP - 822
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
SN - 1598-2998
IS - 4
ER -